JAKARTA – PT Kalbe Farma Tbk (KLBF), through its subsidiary PT Livzon Pharma Indonesia, is investing USD 40 million (approximately IDR 650 billion) to construct an active pharmaceutical ingredients (API) manufacturing facility in the Greenland International Industrial Center (GIIC), Kota Deltamas, Cikarang, West Java.

PT Livzon Pharma Indonesia is a joint venture between Kalbe Farma’s subsidiary, PT Global Chemindo Megatrading, and Lian SGP Holding Pte Ltd, a prominent Chinese pharmaceutical company under the Livzon Group.

In its initial phase, the facility will be equipped with a sterile lyophilised powder API production line, a quality control centre, a power plant, and an emission-free waste treatment system. The plant is scheduled to commence operations by mid-2027.

KLBF Director and Livzon Pharma Commissioner, Mulialie, emphasised that the plant will primarily focus on producing APIs for export markets.

“The strategic partnership with Livzon aims to build API manufacturing capabilities, which will ultimately strengthen Indonesia’s pharmaceutical industry over the long term,” said Mulialie in an official statement on Friday (30/5).

Livzon Pharma General Manager of Operations, Jian Lei, added that the new facility in Indonesia represents a significant milestone in Livzon Group’s global expansion strategy. The plant will manufacture sterile antibiotics, including Vancomycin HCl, Teicoplanin, and Colistimethate Sodium.

The products will comply with the latest Good Manufacturing Practice (GMP) standards set by the FDA, EMEA, and PIC/S.

In addition, the plant aims to obtain halal certification to meet both domestic and international market demands. (DH/ZH)